2015 PFIZER PHARMACEUTICAL MEDICINE ELECTIVE. Last Update: November 17, 2015
|
|
- Blaze Paul
- 8 years ago
- Views:
Transcription
1 2015 PFIZER PHARMACEUTICAL MEDICINE ELECTIVE Last Update: November 17, 2015
2 Table of Contents I. Medicines Regulation... 3 A. Introduction to Regulatory Strategy: Shira Rohde, PhD... 3 B. Introduction to Medical Device Regulation: Mario Mendoza, MD, MS... 3 C. Regulatory Concerns: Advertising & Promotion, USPI overview: Diane Rocco, MBA, MS... 3 D. Overview of Generic Nomenclature Process: Michael Quinlan, BA... 3 E. Overview of Project Management: Amy Novina, PharmD... 4 II. Drug Safety Surveillance... 4 A. Principles of Case Review: Gregory G. Gribko, PharmD, MPH... 4 B. How Epidemiology Adds Value to Drug Safety: Rachel Sobel, PhD... 4 C. Risk Evaluation and Management: Gary G. Wilson, PhD... 4 III. Clinical Pharmacology... 4 A. Clinical Pharmacology in Drug Development: Bimal Malhotra, PhD... 4 B. Drug Metabolizing Enzymes & Pharmacogenomics: Bimal Malhotra, PhD... 5 C. Clinical Pharmacology: Drug-Drug Interaction and Special Population Studies: Manoli Vourvahis, PharmD... 5 IV. Clinical Development... 5 A. Good Clinical Practices: Joan Mackell, PhD... 5 B. Understanding Clinical Trials: Ana Maria Jorga, MD, PhD... 6 C. Phase 3 & 4 Clinical Trial Design: Thomas McRae, MD, MS... 6 D. Statistical Considerations in Clinical Trials: Glenn Pixton, PhD... 6 E. Clinical Trials: TRIAD: Bimal Malhotra, PhD... 6 F. Molecular Epidemiology: Geoff Makinson,... 7 G. Application of Population Pharmcokinetic/Pharmacodynamic Modeling and Simulation in Drug Development: Ellen Q. Wang, PhD... 7 V. Medical Affairs... 7 A. One Physician s Journey in Industry: Julia Perkins, MD... 7 B. Medical Affairs: Konstantinos Tsilkos, MD... 7 C. Publications at Pfizer: Shirley Lam, PharmD... 8 D. Why are you a Physician working at Pfizer?: Denis Keohane, MD, MS; Mike Wajnrajch, MD, MPA; Kevin Williams, MD, JD, MPH... 8 E. Basics of the Pharmaceutical Industry and Why We are Where We Are: How d We Get There: Andrew Clair, PhD
3 F. Investigator Initiated Research: Margaret Essex, PharmD... 8 G. Health Economics & Outcomes Research: Christine Baker, JD, MPH... 9 H. Medical Science Committee for Opioids: Bimal Malhotra, PhD... 9 I. Overview of External Medical Affairs: Paula DeCola, Michael Flesher, Nisith Kumar, Bob Miglani, Charles Thompson... 9 J. Medical Affairs: Phase I-IV studies: Mabel Woloj, PhD... 9 K. Overview of interactions with FDA prior to approval, in label negotiations, and regarding initial promotional materials, Laura Cisar, PhD, MPH
4 I. Medicines Regulation A. Introduction to Regulatory Strategy: Shira Rohde, PhD Medicines Regulation is a key foundation for the Pharmaceutical Medicines Elective. The FDA regulates all aspects of the pharmaceutical industry from early drug development through to post-approval maintenance. The first section of this module introduces the student to global regulatory agencies (with a focus on the U.S. FDA), drug development timelines, the electronic Common Technical Document (ectd), and New Drug Applications (NDAs). B. Introduction to Medical Device Regulation: Mario Mendoza, MD, MS Introduction and general overview of the FDA medical device regulation and clearance pathway. Includes definitions of a medical device, examples of medical devices, FDA CDRH infrastructure and medical device clearance applications (510k, PMA, De Novo, HDE). C. Regulatory Concerns: Advertising & Promotion, USPI overview: Diane Rocco, MBA, MS Provide an introduction to the U.S. Prescribing Information (USPI). Specifically, the format is reviewed and the process by which the content is developed internally and negotiated, and ultimately approved, by the FDA is presented. The NDA/BLA submission process is reviewed in the context of label creation and approval. The importance of the USPI content is discussed relative to the document s use in Advertising and Promotion activities. The process for the development, review, and approval of promotional materials is discussed. Real-product examples of promotional materials are discussed to highlight regulatory considerations in the creation and execution of promotional materials. D. Overview of Generic Nomenclature Process: Michael Quinlan, BA Using real world examples, the overview will explain the purpose of generic names, how they are derived and screened, and the process steps involved in gaining successful outcome on the review of the name. It will take the colleagues on the process journey from name development through the USAN Council & the WHO INN Programme approvals. 3
5 E. Overview of Project Management: Amy Novina, PharmD To gain an understanding of project management, and the the role of the project manager. To provide a brief overview of RU / BU structure. Define governance, decision points, and lastly what data/information is necessary for a DP presentation. II. Drug Safety Surveillance A. Principles of Case Review: Gregory G. Gribko, PharmD, MPH Appreciate how to approach and prepare for a case review as well as understand when they are applied and when case series reviews are useful. Understand terms such as adverse events, adverse reaction, dose response, temporal association, de-challenge, re-challenge, and confounding, and individual case assessments. Understand how to assess drug/adverse event causality. B. How Epidemiology Adds Value to Drug Safety: Rachel Sobel, PhD Understand how pharmacoepidemiological study data is utilized in safety signal management, drug development decision-making, and regulatory strategy. C. Risk Evaluation and Management: Gary G. Wilson, PhD Provide an overview of Risk Evaluation and Mitigation Strategies (REMS-U.S.) and Risk Management Plans (RMP-European Union). III. Clinical Pharmacology A. Clinical Pharmacology in Drug Development: Bimal Malhotra, PhD Provide an overview of Clinical Research during various stages of drug development from Firstin-Human (FIH) to Proof-of-Concept (POC) studies; as well as transition to late-phase 4
6 development (Phase 2) and registration (Phase 3) studies. Understand the importance of Knowledge Management in applying the principles of Enhanced Quantitative Drug Development (EQDD), in practice at Pfizer over the last several years to improve the probability of success of each of our clinical studies through efficient and well-informed study designs. To understand the critical role of clinical pharmacology in traditional areas such as pharmacokinetics/ pharmacodynamics aspects of clinical programs, selection of doses for FIH/POC and Phase 2/3 studies, bioavailability/bioequivalence and drug-drug interactions and special population assessment. Provide an understanding of the application of modeling & simulation to the Phase II/III clinical study design process. B. Drug Metabolizing Enzymes & Pharmacogenomics: Bimal Malhotra, PhD Provide an overview of drug metabolizing enzymes with specific focus on cytochrome P450 (CYP) enzymes. Discuss, specific examples of drugs used to treat overactive bladder (tolterodine and fesoterodine) and depression (venlafaxine and desvenlafaxine) as well as attention deficit hyperactive disorder (atomoxetine), where CYP2D6 activity is implicated in the metabolism of the parent drug. C. Clinical Pharmacology: Drug-Drug Interaction and Special Population Studies: Manoli Vourvahis, PharmD Provide an overview of drug metabolizing enzymes and drug transporters with a detailed discussion on special population and drug-drug interaction study strategy, study design, and analysis. Examples of special population studies discussed include assessing pharmacokinetics in pediatrics, hepatic impairment and renal impairment populations. Provide an overview on how to interpret the drug-drug interaction and special population sections of the product label. IV. Clinical Development A. Good Clinical Practices: Joan Mackell, PhD Discuss the various clinical and historical events that led to the evolution and development of Good Clinical Practices (GCPs), including laws, regulations, the Declaration of Helsinki and the contemporary international perspective, as developed through the International Conference on Harmonization (ICH) Guidelines. Provide an understanding of the rationale for these laws, regulations and guidelines, ensuring that clinical research is consistently performed to high 5
7 ethical and scientific standards, with the primary considerations being to protect the rights and safety of clinical subjects and ensure quality, integrity, consistency and reproducibility of data. B. Understanding Clinical Trials: Ana Maria Jorga, MD, PhD Provide an understanding of different clinical trial designs, basic study terminology, phases of drug development, protocol design, and aspects of study participation (informed consent, patient safety and protection). Provide an understanding of late stage clinical trial design (Phase 3 & 4). Protocol design and considerations including: demographics of study population, regulatory considerations, cultural aspects (local studies), and statistical considerations. C. Phase 3 & 4 Clinical Trial Design: Thomas McRae, MD, MS Provide an understanding of late stage clinical trial design (Phase 3 & 4). Protocol design and considerations including: demographics of study population, regulatory considerations, cultural aspects (local studies), and statistical considerations. D. Statistical Considerations in Clinical Trials: Glenn Pixton, PhD Introduce statistical concepts and how they relate to study design. Understand how study design affects data analysis. Provide an introduction to basic terms such as Type I and II error, randomization, bias, types of comparisons, sample size, and interim analysis. E. Clinical Trials: TRIAD: Bimal Malhotra, PhD Provide an introduction to Pfizer design and conduct of clinical research and how it is enabled through study teams comprised of a TRIAD at the core, representing three critical and essential functional lines: Clinical Sciences, Clinical Pharmacology, and Statistics. Discuss the role and responsibilities of the TRIAD study team; the TRIAD is expected to consider multiple study design options and is encouraged to use quantitative tools such as modeling & simulation exercises to choose an option that provides optimum probability of success. A clinical program or trial may be endorsed to proceed only when the TRIAD has demonstrated application of EQDD best practices. 6
8 F. Molecular Epidemiology: Geoff Makinson, Provide an introduction to the role of molecular epidemiology and its function across Global Health & Value, Outcomes & Evidence, and R&D. G. Application of Population Pharmcokinetic/Pharmacodynamic Modeling and Simulation in Drug Development: Ellen Q. Wang, PhD Provide an example of how population pharmacokinetic/pharmacodynamic (PK/PD) modeling is used to establish the quantitative relationship between drug dose, plasma concentration, and pharmacodynamic response. Provide an understanding of how clinical trial simulations were used (using the final population PK/PD model) to help select the most appropriate dose and regimen for a global Phase 3 program. V. Medical Affairs A. One Physician s Journey in Industry: Julia Perkins, MD Provide an overview of how much clinical training one needs to work in industry, how to apply it and which areas within industry are available to a physician for career development. Understand the pros and cons of working in pharmaceutical medicine versus clinical medicine. Deck entitled: Fellows Career Day: Fellowship to Industry B. Medical Affairs: Konstantinos Tsilkos, MD Provide a clear overview of the role of medical affairs within an industry setting. Including, but not limited to: providing a medical perspective to drug product development, provide support for marketed products (ie, RC committees), ensure adherence to relevant scientific and legal guidelines, and provide general as well as specialized expertise per therapeutic area as required internally and externally. Finally, to act as the company subject matter expert in a given therapeutic area/areas and interface with all sectors of the medical profession. 7
9 C. Publications at Pfizer: Shirley Lam, PharmD Provide an overview of External publication guidelines (ICMJE) and internal requirements (SOPs CT20 and CT37). D. Why are you a Physician working at Pfizer?: Denis Keohane, MD, MS; Mike Wajnrajch, MD, MPA; Kevin Williams, MD, JD, MPH Provides an overview of the different roles in industry as well as the paths a physician can embark on in order to begin a career in industry. It provides medical students with the opportunity to engage and interact with a number of physicians who have chosen a career in industry. Presenters discuss their backgrounds and career paths that led them to taking a position working at Pfizer. During this interactive session, students have the opportunity to ask questions and have a dialogue with Pfizer physicians working in the Medical Affairs organization. These in-depth conversations cover a variety of topics ranging from the advantages and disadvantages of choosing a career in industry and the different types of career opportunities available for physicians within the pharmaceutical industry. E. Basics of the Pharmaceutical Industry and Why We are Where We Are: How d We Get There: Andrew Clair, PhD Provide an understanding of various events which have led to the current state of the pharmaceutical industry. Other areas covered include an introduction to drug development, preclinical and clinical studies, regulatory history, origin of Good Clinical Practices and FDA warning letters due to clinical study violations. F. Investigator Initiated Research: Margaret Essex, PharmD Provide an understanding of Pfizer s commitment to fostering new relationships with scientists and nurturing top research talent. Provides an introduction to and overview of the Pfizer Investigator Initiated Research program, which serves as an incubator for research projects that 8
10 advance medical and scientific knowledge about our therapies and generates promising medical interventions. The role that Medical Affairs plays in this process is highlighted. G. Health Economics & Outcomes Research: Christine Baker, JD, MPH s Overview of health economics and outcomes research methodologies and how they are used to support Pfizer medicine market access of H. Medical Science Committee for Opioids: Bimal Malhotra, PhD s Provide an overview of the Medical Science Committee (MSC) members, role, and function within Pfizer. The Medical Science Committee (MSC) members typically include: Clinical Sciences, Clinical Pharmacology, Statistics, Regulatory Affairs, Medical Affairs, Pharmaceutical Sciences, Chemistry/Manufacturing/Controls, Project Management, and regional Medical Directors. The agenda of each meeting varies depending on the evolution of the program status. At a given MSC meeting, the team may discuss the evolving program strategy, functional line updates, clinical study design proposal(s), emerging study results, competitive updates etc. Students may be given an opportunity to attend a scheduled MSC meeting for the Abuse- Deterrent Opioids program at Pfizer. I. Overview of External Medical Affairs: Paula DeCola, Michael Flesher, Nisith Kumar, Bob Miglani, Charles Thompson s To provide an overview of Pfizer s External Medical Affairs group which supports the safe, effective, and appropriate use of Pfizer human health products across the lifecycle for all patients across the life course. This is accomplished in collaboration and partnership with the leadership of healthcare organizations, in order to shape the healthcare landscape, increase access to the Pfizer portfolio and improve patient outcomes. J. Medical Affairs: Phase I-IV studies: Mabel Woloj, PhD s Provide a basic understanding of clinical drug development phases. Including clinical and medical affairs function/roles throughout the drug development process, inclusive of drug discovery through drug approval and lifecycle management. 9
11 K. Overview of interactions with FDA prior to approval, in label negotiations, and regarding initial promotional materials, Laura Cisar, PhD, MPH s Provide an overview of how to find label information, FDA review documents, and document from Oncology Division Advisory Committee meetings: Demonstrate link to FDA label information, and how to find reviewer comments Demonstrate link to oncology advisory committee meeting materials cdrugsadvisorycommittee/ucm htm Provide an understanding of interactions with the FDA prior to approval, in label negotiations, and regarding promotional material sent in for pre-clearance: Review publication of phase 3 pivotal trial for Inlyta, and FDA guidance Good Reprint Practices for the Distribution of medical Journal Articles and medical Scientific Reference Publications on Unapproved New Uses of Approved Drugs and Approved or Cleared Medical Devices (available) Review types of information included in a briefing document prior to an ODAC (available) Review specific example (Inlyta) of label negotiations with the FDA, in parallel looking at the label Review OPDP comments on preclearance materials, keeping in mind label negotiations and publication of phase 3 study Review subsequent revisions to promotional materials 10
Proof-of-Concept Studies and the End of Phase IIa Meeting with the FDA
Medpace Discovery Series presents Proof-of-Concept Studies and the End of Phase IIa Meeting with the FDA DR. JIM WEI: Today my topic is going to be Proof-of-Concept Studies and FDA End of Phase 2a Meetings
More informationOverview of Drug Development: the Regulatory Process
Overview of Drug Development: the Regulatory Process Roger D. Nolan, PhD Director, Project Operations Calvert Research Institute November, 2006 Adapted from course taught by Cato Research Background: Roger
More informationCLINICAL PHARMACOLOGY
0 :: 2 v01 x y p.345 B xxx.:: B A x y pval«««[xy] -løøøø xxx.:: øøøø -0.02-0.01-0.00 0.00 0.01 0.02.1.2 A PHARMATRAIN CENTRE OF EXCELLENCE EXPLORATORY & CONFIRMATORY CLINICAL DEVELOPMENT: CLINICAL PHARMACOLOGY
More informationIntroduction to Post marketing Drug Safety Surveillance: Pharmacovigilance in FDA/CDER
Introduction to Post marketing Drug Safety Surveillance: Pharmacovigilance in FDA/CDER LT Andrew Fine, Pharm.D., BCPS Safety Evaluator Division of Pharmacovigilance Office of Pharmacovigilance and Epidemiology
More informationOversight of Clinical Trials in Europe - Member State perspective. Gunnar Danielsson Senior Expert Pharmaceutical Inspector
Oversight of Clinical Trials in Europe - Member State perspective Gunnar Danielsson Senior Expert Pharmaceutical Inspector Oversight of Clinical Trials Oversight of clinical trials occur on many different
More informationCareers in Medical and Scientific Writing
Careers in Medical and Scientific Writing Laura McCormick, PhD Vice President Associate Practice Leader Tamara Fink, PhD Associate Scientific Director ProEd Communications, Inc Beachwood, Ohio Agenda Introduction
More informationEffective Outsourcing of Clinical Pharmacology Studies in Europe. John Horkulak Executive Director, Eurasian External Clinical Study Operations
Effective Outsourcing of Clinical Pharmacology Studies in Europe John Horkulak Executive Director, Eurasian External Clinical Study Operations Key Questions Do clinical pharmacology studies require a different
More informationSafety Risk Management Company Perspective
Safety Risk Management Company Perspective Akihisa Harada, MD, Ph.D VP, Development Japan Pfizer Japan Inc. R&D Head Club Agenda REMS in FDAAA Safety Risk Management throughout a Drug s Lifecycle Risk
More informationPost-Doctoral Pharmaceutical Industry Fellowships. Two-Year Clinical Development Program Two-Year Clinical Safety Program
Post-Doctoral Pharmaceutical Industry Fellowships Two-Year Clinical Development Program Two-Year Clinical Safety Program Today, we innovate by creating new medicines, as well as new methods of drug discovery
More informationPharmD Postdoctoral Fellowship Program
Novartis Institutes for Biomedical Research and Massachusetts College of Pharmacy and Health Sciences, Worcester/Manchester PharmD Postdoctoral Fellowship Program Introduction Fellowship training in the
More informationSYLLABUS. Drug development in a New Era: NYU GSAS, MSc, Sackler, SOM 2012
Drug development in a New Era: NYU GSAS, MSc, Sackler, SOM 2012 Course Description: Bringing a new chemical entity, drug, or device to the consumer market is a necessary but intricate, expensive, complicated,
More informationImporting pharmaceutical products to China
Importing pharmaceutical products to China Imported pharmaceutical products need pre-market approval before entering the Chinese market Imported drugs for human use are required to obtain pre-market approval
More informationA clinical research organization
A clinical research organization About Us State of art facility. All clinical trials carried out in accordance with ICH GCP guidelines. Quality services within stipulated time period. Team of experienced
More informationClinical Trials and Safety Surveillance of Drugs in Development
Clinical Trials and Safety Surveillance of Drugs in Development Hoda Eid, M.Sc., Ph.D. Manager, ADR Unit Office of Clinical Trials Therapeutic Products Directorate hoda_eid@hc-sc.gc.ca Overview Clinical
More informationMaster's Clinical Pharmacy (Thesis Track)
Master's Clinical Pharmacy (Thesis Track) I. GENERAL RULES CONDITIONS: Plan Number 3 \ 12 06 2010 T 1. This plan conforms to the valid regulations of the programs of graduate studies. 2. Areas of specialty
More informationGoals & Objectives. Drug Development & the FDA Pharmacy 309. Outline. An History of Disasters. Be able to describe
Drug Development & the FDA Pharmacy 309 Tom Hazlet, Pharm.D., Dr.P.H. 616-2732 thazlet@u... Goals & Objectives Be able to describe the major regulatory events in the drug development process the concepts
More information298.015) UC 6:30 8:20 PM
Course Description: This course is an in depth review of the history, authorizing statute and regulatory authority of US FDA and the influence and impact of FDA on science and health policy. Drug development,
More informationThe Product Review Life Cycle A Brief Overview
Stat & Quant Mthds Pharm Reg (Spring 2, 2014) Lecture 2,Week 1 1 The review process developed over a 40 year period and has been influenced by 5 Prescription User Fee Act renewals Time frames for review
More informationSheffield Kidney Institute. Planning a Clinical Trial
Planning a Clinical Trial Clinical Trials Testing a new drug Ethical Issues Liability and Indemnity Trial Design Trial Protocol Statistical analysis Clinical Trials Phase I: Phase II: Phase III: Phase
More informationChallenges in the Regulation of Pediatric Clinical Trials
Challenges in the Regulation of Pediatric Clinical Trials Wilson W. Bryan, M.D. FDA / CBER / OCTGT wilson.bryan@fda.hhs.gov National Institutes of Health Recombinant DNA Advisory Committee (RAC) Meeting
More informationRAPS ONLINE UNIVERSITY
RAPS ONLINE UNIVERSITY Practical education and training for business success. For regulatory professionals, there is only one name to know and trust for online education and training RAPS Online University.
More information4.1 Objectives of Clinical Trial Assessment
L1 4.1 Objectives of Clinical Trial Assessment Presentation to APEC Preliminary Workshop on Review of Drug Development in Clinical Trials Celia Lourenco, PhD, Manager, Clinical Group I Office of Clinical
More informationGuidance for Industry
Guidance for Industry End-of-Phase 2A Meetings U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) September 2009 Procedural Guidance
More informationSafety Is Global: Contemporary Pharmacovigilance and Medical Product Risk Management Strategies
Safety Is Global: Contemporary Pharmacovigilance and Medical Product Risk Management Strategies CLICK HERE to register. PROGRAM COMMITTEE WHO SHOULD ATTEND This program will benefit professionals with
More informationRoles & Responsibilities of the Sponsor
Roles & Responsibilities of the Sponsor Developed by Center for Cancer Research, National Cancer Institute, NIH Endorsed by the CTN SIG Leadership Group Objectives Funding for clinical research comes from
More informationMasters of Science in Clinical Research (MSCR) Curriculum. Goal/Objective of the MSCR
Masters of Science in Clinical (MSCR) Curriculum Goal/Objective of the MSCR The MSCR program is an interdisciplinary research degree program housed within the Department of Epidemiology in the School of
More informationGlobal regulatory affairs role in the biopharmaceutical industry
CHAPTER TWO Global affairs role in the biopharmaceutical industry 2.1 Overview 2.2 Global affairs organization 2.3 Role of global affairs 2.4 Key functions and activities 2.5 Global strategy 2.6 Global
More informationManchester Pharmacy School. www.manchester.ac.uk/pharmacy
Manchester Pharmacy School Postgraduate study from Continuous Professional Development (CPD), Certificate, Diploma to Masters (MSc) with flexible, modular learning. The University of Manchester has a proud
More informationMedicine Safety Glossary
The following definitions are provided as a resource to supplement the information provided in the Medicine Safety Education section of the Pfizer.com Web site; they are not intended as a comprehensive
More informationCLINICAL TRIALS SHOULD YOU PARTICIPATE? by Gwen L. Nichols, MD
CLINICAL TRIALS SHOULD YOU PARTICIPATE? by Gwen L. Nichols, MD Gwen L. Nichols, M.D., is currently the Oncology Site Head of the Roche Translational Clinical Research Center at Hoffman- LaRoche. In this
More informationA Cost Effective Way to De Risk Biomarker Clinical Trials: Early Development Considerations
A Cost Effective Way to De Risk Biomarker Clinical Trials: Early Development Considerations Ce3, Inc. and Insight Genetics, Inc. Oncology Forum July 15, 2015 Agenda Introductions Definitions Regulations
More informationHistory and Principles of Good Clinical Practice
History and Principles of Good Clinical Practice Cristina E. Torres, Ph.D. Social Science Professor, UPM-NIH FERCAP Coordinator ICH: International Conference on Harmonization GCP: Good Clinical Practices
More informationPHARMACEUTICAL INDUSTRY Fellowship Program
PHARMACEUTICAL INDUSTRY Fellowship Program USC School of Pharmacy 2015-2016 In partnership with ABOUT OUR COMPANY Allergan, headquartered in Dublin, Ireland, is a unique, global pharmaceutical company
More informationEarly Phase Clinical Drug Development
Massachusetts College of Pharmacy and Health Sciences, Worcester, MA Post-PharmD Fellowship Program at Novartis Institutes for BioMedical Research, Cambridge, MA Early Phase Clinical Drug Development Introduction
More informationInstitute for Safe Medication Practices
Institute for Safe Medication Practices 1800 Byberry Road, Suite 810 Huntingdon Valley, PA 19006 FOR MORE INFORMATION, CONTACT : Michael A. Donio, MPA Marketing & Consumer Affairs 215-947-7797 Mdonio@ismp.org
More informationMasters Learning mode (Форма обучения)
Program Title (Название программы): Pharmacology Degree (Степень) Masters Learning mode (Форма обучения) Full-time and part-time Duration of study (Продолжительность программы) 2 years (4 years part time)
More informationA responsible approach to clinical trials. Bioethics in action
A responsible approach to clinical trials Bioethics in action What is bioethics? At Novo Nordisk bioethics is the expression used for all ethical issues related to the use of life science technologies
More informationClinical trials for medical devices: FDA and the IDE process
Clinical trials for medical devices: FDA and the IDE process Owen Faris, Ph.D. Deputy Director Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health,
More informationAchieving Regulatory Success: Areas of focus for biotechnology companies. Michael J. Schlosser, PhD, DABT April 21, 2013
Achieving Regulatory Success: Areas of focus for biotechnology companies Michael J. Schlosser, PhD, DABT April 21, 2013 Regulatory Success Outline Regulatory Initiatives Regulatory Science Pre-Regulatory
More informationThere are 2 types of clinical trials that are of interest to the. The Clinical Trials Network of the Society of Nuclear Medicine
The Clinical Trials Network of the Society of Nuclear Medicine Michael M. Graham, PhD, MD The Clinical Trials Network of the Society of Nuclear Medicine was formed to provide quality assurance of both
More informationAbt Associates Inc. Abt Associates Clinical Trials Comprehensive clinical research services
Abt Associates Inc. Abt Associates Clinical Trials Comprehensive clinical research services Providing a wide range of clinical research services Abt Associates Clinical Trials (AACT) is dedicated to providing
More informationIs a Career in the. Pharmaceutical. Check out our online Student Center to find out more: www.aaps.org/forstudents
Is a Career in the Pharmaceutical Sciences Right for Me? Check out our online Student Center to find out more: www.aaps.org/forstudents How Do I Know If a Career in the Pharmaceutical Sciences is Right
More informationGENERAL CONSIDERATIONS FOR CLINICAL TRIALS E8
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE GENERAL CONSIDERATIONS FOR CLINICAL TRIALS E8 Current
More informationR & D S E N I O R L E A D E R S H I P B R I E F. The Adoption and Impact of Adaptive Trial Designs
R & D S E N I O R L E A D E R S H I P B R I E F The Adoption and Impact of Adaptive Trial Designs page 1 R & D S E N I O R L E A D E R S H I P B R I E F The Adoption and Impact of Adaptive Trial Designs
More informationCareers in Biostatistics and Clinical SAS Programming An Overview for the Uninitiated Justina M. Flavin, Independent Consultant, San Diego, CA
PharmaSUG 2014 Paper CP07 Careers in Biostatistics and Clinical SAS Programming An Overview for the Uninitiated Justina M. Flavin, Independent Consultant, San Diego, CA ABSTRACT In the biopharmaceutical
More informationRisk Management Plan (RMP) on Biologicals and NCE
Transformation towards a New Regulatory Paradigm Risk Management Plan (RMP) on Biologicals and NCE Junko SATO International Coordination Officer PMDA, Japan 1 2 Pharmaceuticals and Medical Devices Agency
More informationFLORIDA A&M UNIVERSITY AND BRISTOL-MYERS SQUIBB PHARMACEUTICAL INDUSTRY RESIDENCY PROGRAM 2015-2016
FLORIDA A&M UNIVERSITY AND BRISTOL-MYERS SQUIBB PHARMACEUTICAL INDUSTRY RESIDENCY PROGRAM 2015-2016 TABLE OF CONTENTS Dear Prospective Residents.........................................................
More informationResearch on Research: Learning about Phase 1 Trials
CLINICAL CASE STUDY SERIES Research on Research: Learning about Phase 1 Trials Phases of clinical trial investigation are described in some detail in the Code of Federal Regulations. Phase 1 is described
More informationDrug Development Models in China and the Impact on Multinational Pharmaceutical Companies
Drug Development Models in China and the Impact on Multinational Pharmaceutical Companies By Ling Su, Ph.D. China represents a huge potential opportunity for the pharmaceutical industry in both commercial
More informationMINISTRY OF HIGHER EDUCATION UNIVERSITY OF HAIL COLLEGE OF PHARMACY
MINISTRY OF HIGHER EDUCATION UNIVERSITY OF HAIL COLLEGE OF PHARMACY Academic Reference Standards of Pharm.-D Program College of Pharmacy-University of Hail May The Major shift in the health-care system
More informationFirst In Human Pediatric Trials and Safety Assessment for Rare and Orphan Diseases
First In Human Pediatric Trials and Safety Assessment for Rare and Orphan Diseases Andrew E. Mulberg, MD, FAAP Division Deputy Director OND/ODE3/DGIEP FDA Partnership is the Key Coming together is a beginning;
More informationCOMMITTEE FOR VETERINARY MEDICINAL PRODUCTS GUIDELINE FOR THE CONDUCT OF POST-MARKETING SURVEILLANCE STUDIES OF VETERINARY MEDICINAL PRODUCTS
The European Agency for the Evaluation of Medicinal Products Veterinary Medicines and Information Technology EMEA/CVMP/044/99-FINAL COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS GUIDELINE FOR THE CONDUCT
More informationexactly. The need for efficiency in developing effective new therapeutics has never been greater.
exactly. The need for efficiency in developing effective new therapeutics has never been greater. As demands on the global healthcare system increase and treating disease becomes more complex, the research,
More informationClinical Trial Protocol Development. Developed by Center for Cancer Research, National Cancer Institute Endorsed by the CTN SIG Leadership Group
Clinical Trial Protocol Development Developed by Center for Cancer Research, National Cancer Institute Endorsed by the CTN SIG Leadership Group Objectives The clinical trial protocol is the heart of any
More informationDMPK: Experimentation & Data
DMPK: Experimentation & Data Interpretation Mingshe Zhu, Mike S. Lee, Naidong Weng, and Mark Hayward Prerequisite: Entry-level scientists with hands on experience in LC/MS as well as advanced students
More informationRisk Management Plan (RMP) Guidance (Draft)
Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare Translated by Pharmaceuticals and Medical Devices Agency Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour
More informationA competency framework for all prescribers updated draft for consultation
A competency framework for all prescribers updated draft for consultation Consultation closes 15 April 2016 Contents 1 Introduction... 3 2 Uses of the framework... 4 3 Scope of the competency framework...
More informationDoctor of Pharmacy/Master of Public Health Joint Degree Program
Rationale Doctor of Pharmacy/Master of Public Health Joint Degree Program The Master of Public Health (MPH) program is designed to prepare students to become effective leaders, practitioners, researchers,
More informationEthics and Scientific Oversight for Phase 1 Clinical Trials in Hong Kong. Sydney TANG Chairman, HKU/HA HKW IRB November 21, 2015
Ethics and Scientific Oversight for Phase 1 Clinical Trials in Hong Kong Sydney TANG Chairman, HKU/HA HKW IRB November 21, 2015 Clinical Trials at HKU Phase 1 Phase II Phase III Phase IV Conducted on patient
More informationQuality by Design Concept
3rd Jerusalem Conference on Quality and Pharma Sciences 6-7 June, 2012 QbD in Clinical Research - Where Can QbD Impact Clinical Research Practices? Dr. Yafit Stark Vice President, TEVA Pharmaceutical Industries,
More informationPharmaceutical Sciences
Is a Career in the Pharmaceutical Sciences Right for Me? Check out our online Student Center to find out more: www.aapspharmaceutica.com/students How do I know if a career in the pharmaceutical sciences
More informationFormal FDA Meeting Request: Guidance and Template
Formal FDA Meeting Request: Guidance and Template ICTR Navigators July 23, 2011 Version 2.0 Page 1 of 20 1.0 Table of Contents Section Page 1.0 Table of Contents 2 2.0 Abbreviations 2 3.0 FDA Regulations
More informationPOLICY AND PROCEDURES OFFICE OF NEW DRUGS. Good Review Practice: Management of Breakthrough Therapy-Designated Drugs and Biologics.
POLICY AND PROCEDURES OFFICE OF NEW DRUGS Good Review Practice: Management of Breakthrough Therapy-Designated Drugs and Biologics Table of Contents PURPOSE...1 BACKGROUND...2 POLICY...3 ROLES AND RESPONSIBILITIES...4
More informationINTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE E15
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE DEFINITIONS FOR GENOMIC BIOMARKERS, PHARMACOGENOMICS,
More informationRAC (US) Examination Study Checklist
RAC (US) Examination Study Checklist Instructions: Use this checklist to track your progress when preparing for the RAC (US) certification examination. When you begin your studying, each task statement
More informationThe Role of Regional Medical Advisor (RMA)-Field Medical. Dr. Aju Abraham Varghese Pfizer India. Feb 22 nd 2014
The Role of Regional Medical Advisor (RMA)-Field Medical Dr. Aju Abraham Varghese Pfizer India Feb 22 nd 2014 Disclaimer The opinions expressed in this presentation are solely those of the presenter and
More informationHow To Understand The Pharmacology Of The Pharmaceutical Industry
It; MM MODERN Ul NDUSTRY 77 /
More informationThe MSCR Curriculum and Its Advantages
Masters of Science in Clinical Research (MSCR) Curriculum Goal/Objective of the MSCR The MSCR program is an interdisciplinary research degree program housed within the Department of Epidemiology in the
More informationEU DIRECTIVE ON GOOD CLINICAL PRACTICE IN CLINICAL TRIALS DH & MHRA BRIEFING NOTE
EU DIRECTIVE ON GOOD CLINICAL PRACTICE IN CLINICAL TRIALS DH & MHRA BRIEFING NOTE Purpose 1. The Clinical Trials Directive 2001/20/EC heralds certain additional responsibilities for the Medicines and Healthcare
More informationHarmonized Core Competencies in Clinical Research: evolutions and next steps for meeting the challenge
Harmonized Core Competencies in Clinical Research: evolutions and next steps for meeting the challenge Master of Applied Clinical and Preclinical Research macpr.osu.edu Consortium of Academic Programs
More informationIntroduction to Clinical Research
Introduction to Clinical Research NCURA Region I Spring Meeting May 5, 2015 Agenda Introductions Brief History of Clinical Research Clinical Research in Context Clinical Research Compliance Clinical Research
More informationStrategic Consulting Services
Services 1 Leadership Team Mark Levonyak President mlevonyak@davaonc.com Mobile: 214.460.5051 Martin W. Lee, MD EVP, Clinical Trial Services mlee@davaonc.com Mobile: 952.373.1405 John Eckardt, MD Chief
More informationCTD Dossier Preparation. Sr.Manager-Regulatory Affairs
CTD Dossier Preparation K. Srikantha Reddy Sr.Manager-Regulatory Affairs Medreich Limited Srikanth.k@medreich.com CTD Dossier Preparation CTD (Common Technical Document) contains 5 modules Module 1 Module
More informationST. MICHAEL S HOSPITAL Guidelines for Reporting Serious Adverse Events / Unanticipated Problems to the SMH Research Ethics Board (REB) July 09, 2014
ST. MICHAEL S HOSPITAL Guidelines for Reporting Serious Adverse Events / Unanticipated Problems to the SMH Research Ethics Board (REB) July 09, 2014 1. Introduction The St. Michael s Hospital (SMH) REB
More informationGlossary of Clinical Trial Terms
Glossary of Clinical Trial Terms ADVERSE REACTION: (Adverse Event): Also known as side effects, adverse reactions include any undesired actions or effects of the experimental drug or treatment. Experimental
More informationRESEARCH INVOLVING HUMAN SUBJECTS
RESEARCH INVOLVING HUMAN SUBJECTS GUIDELINES FOR IRBS PART A: INTRODUCTION AND CURRENT FRAMEWORK SECTION I: INTRODUCTION 1. Introduction About these Guidelines 1.1. The Bioethics Advisory Committee (BAC)
More informationThe Promise and Challenge of Adaptive Design in Oncology Trials
THE POWER OFx Experts. Experience. Execution. The Promise and Challenge of Adaptive Design in Oncology Trials Clinical oncology trials are more complex and time consuming than those in any other therapeutic
More informationLocation for Trials- Global Considerations A Pharma Perspective. Carlo Maccarrone Assoc. Director, Clinical Research GSK Australia 7 May 2014
Location for Trials- Global Considerations A Pharma Perspective Carlo Maccarrone Assoc. Director, Clinical Research GSK Australia 7 May 2014 Why Choose Australia for Clinical Trials? What is he saying
More informationGuidance for Industry FDA Approval of New Cancer Treatment Uses for Marketed Drug and Biological Products
Guidance for Industry FDA Approval of New Cancer Treatment Uses for Marketed Drug and Biological Products U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation
More informationMOLECULAR PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
MOLECULAR PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS R. M. Weinshilboum, M.D., Program Director L. Wang, M.D., Ph.D., Program Co-Director D. C. Mays, Ph.D., Associate Program Director Ph.D. Degree Course
More informationCERTIFICATE IN CLINICAL TRIAL MANAGEMENT
Temple University - School of Pharmacy 425 Commerce Drive, Suite 175 Fort Washington, PA 19034-2713 Phone: 267.468.8560 Fax: 267.468.8565 CERTIFICATE IN CLINICAL TRIAL MANAGEMENT Designed for Pharmaceutical
More informationClinical Data Management Overview
The 2 nd Clinical Data Management Training Clinical Data Management Overview Andrew Taylor ( 安 泰 乐 ), M.S. Head of Clinical Data Management August 30, 2010 Learning Objectives Overview of Process Related
More informationRegulatory Considerations for Conducting Clinical Trials In India
Regulatory Considerations for Conducting Clinical Trials In India By Mukesh Kumar, PhD & Surinder Kher, MD In the last few years, there has been increasing interest in the pharmaceutical industry in outsourcing
More informationAssociate Group Director, Regulatory Intelligence & Policy
Date: 06/24/16 Associate Group Director, Regulatory Intelligence & Policy Job ID: 2974410847 Job Function Project Management Regulatory Affairs Location United States - District of Columbia Washington
More informationSchool of Pharmacy TEMPLE UNIVERSITY
School of Pharmacy TEMPLE UNIVERSITY Regulatory Affairs and Quality Assurance Graduate Program Te mple Unive rsity School of Pharmacy Re gulatory Affairs and Quality Assurance Graduate Program 4 25 Comme
More informationGuideline for Industry
Guideline for Industry The Extent of Population Exposure to Assess Clinical Safety: For Drugs Intended for Longterm Treatment of Non-Life- Threatening Conditions ICH-E1A March 1995 GUIDELINE FOR INDUSTRY
More informationThe New EU Clinical Trials Regulation: The Good, the Bad, the Ugly
A Full-Service International CRO The New EU Clinical Trials Regulation: The Good, the Bad, the Ugly Dr. Martine Dehlinger-Kremer Vice President, Global Medical and Regulatory Affairs The original intent
More informationRevised checklist for BA/BE NOC effective from 01 st February 2014 (Draft for comments before 25 Jan 14)
Revised checklist for BA/BE NOC effective from 01 st February 2014 (Draft for comments before 25 Jan 14) Documents to be submitted for grant of permission to conduct BA/BE studies in Human Subjects/Patients
More informationHow To Weigh Data From A Study
PRINCIPLES ON RESPONSIBLE SHARING OF TRUTHFUL AND NON-MISLEADING INFORMATION ABOUT MEDICINES WITH HEALTH CARE PROFESSIONALS AND PAYERS INTRODUCTION In the era of data-driven medicine, where all parties
More informationNot All Clinical Trials Are Created Equal Understanding the Different Phases
Not All Clinical Trials Are Created Equal Understanding the Different Phases This chapter will help you understand the differences between the various clinical trial phases and how these differences impact
More informationRisk Management in the Pharmaceutical Industry. Elena Apetri, Global Medical Safety Surveillance Schering AG
Risk Management in the Pharmaceutical Industry Elena Apetri, Global Medical Safety Surveillance Schering AG Topics Environment Safety Risk Management Guidance Safety RM Systems Signal detection and evaluation
More informationGraduate Program Objective #1 Course Objectives
1 Graduate Program Objective #1: Integrate nursing science and theory, biophysical, psychosocial, ethical, analytical, and organizational science as the foundation for the highest level of nursing practice.
More information10/31/2014. Medication Adherence: Development of an EMR tool to monitor oral medication compliance. Conflict of Interest Disclosures.
Medication Adherence: Development of an EMR tool to monitor oral medication compliance Donna Williams, RN PHN Carol Bell, NP MSN Andrea Linder, RN MS CCRC Clinical Research Nurses Stanford University SOM
More informationPharmacology skills for drug discovery. Why is pharmacology important?
skills for drug discovery Why is pharmacology important?, the science underlying the interaction between chemicals and living systems, emerged as a distinct discipline allied to medicine in the mid-19th
More informationCTC Technology Readiness Levels
CTC Technology Readiness Levels Readiness: Software Development (Adapted from CECOM s Software Technology Readiness Levels) Level 1: Basic principles observed and reported. Lowest level of software readiness.
More informationStandards of Practice for Pharmacists and Pharmacy Technicians
Standards of Practice for Pharmacists and Pharmacy Technicians Introduction These standards are made under the authority of Section 133 of the Health Professions Act. They are one component of the law
More informationTotal Product Lifecycle Solutions from NSF Health Sciences Medical Devices
Total Product Lifecycle Solutions from NSF Health Sciences Medical Devices Experts in medical device quality systems, compliance, regulatory affairs, auditing and training www.nsf.org The Right People.
More informationJob Profile Clinical Research Associate III (CRA)
PART 1 - PROFILE You are an experienced CRA with a strong background in Clinical Research who is passionate about drug development and are seeking a challenging and rewarding career in a quality focussed
More informationWaiver to Allow Participation in a Food and Drug Administration Advisory Committee
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Silver Spring MD 20993 Waiver to Allow Participation in a Food and Drug Administration Advisory Committee DATE:
More informationTemple University - School of Pharmacy 425 Commerce Drive, Suite 175 Fort Washington, PA 19034. Phone: 267.468.8560 Fax: 267.468.
Temple University - School of Pharmacy 425 Commerce Drive, Suite 175 Fort Washington, PA 19034 Phone: 267.468.8560 Fax: 267.468.8565 POST-MASTER S CERTIFICATE in CLINICAL TRIAL MANAGMENT Designed for Pharmaceutical
More information